A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy
A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy. American Society for Hematology 47th Annual Meeting. 2005.